Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial
The 2023 OASIS 1 trial evaluated the efficacy and safety of oral semaglutide 50 mg daily in 667 adults with overweight or obesity without type 2 diabetes. Over 68 weeks, participants receiving semaglutide experienced a mean weight loss of 15.1%, compared to 2.4% with placebo. Notably, 85% of the semaglutide
June 26, 2025
No Comments